CN114568627A - 一种可改善微循环的营养代餐粉及其制备方法 - Google Patents
一种可改善微循环的营养代餐粉及其制备方法 Download PDFInfo
- Publication number
- CN114568627A CN114568627A CN202210265181.5A CN202210265181A CN114568627A CN 114568627 A CN114568627 A CN 114568627A CN 202210265181 A CN202210265181 A CN 202210265181A CN 114568627 A CN114568627 A CN 114568627A
- Authority
- CN
- China
- Prior art keywords
- meal replacement
- powder
- parts
- replacement powder
- nutritional meal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 126
- 235000012054 meals Nutrition 0.000 title claims abstract description 81
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 49
- 230000004089 microcirculation Effects 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 241000251511 Holothuroidea Species 0.000 claims abstract description 26
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract description 22
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 22
- 240000000249 Morus alba Species 0.000 claims abstract description 18
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 18
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 15
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 15
- 235000021119 whey protein Nutrition 0.000 claims abstract description 15
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 244000075850 Avena orientalis Species 0.000 claims abstract description 9
- 229960003080 taurine Drugs 0.000 claims abstract description 6
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 3
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 7
- 235000013373 food additive Nutrition 0.000 claims description 6
- 239000002778 food additive Substances 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 241000209140 Triticum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 229930003451 Vitamin B1 Natural products 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- 235000010374 vitamin B1 Nutrition 0.000 claims description 4
- 239000011691 vitamin B1 Substances 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 238000009924 canning Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 22
- 210000004204 blood vessel Anatomy 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000004087 circulation Effects 0.000 abstract description 4
- 230000000916 dilatatory effect Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000006872 improvement Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 7
- 235000007319 Avena orientalis Nutrition 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000756042 Polygonatum Species 0.000 description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 4
- 235000005493 rutin Nutrition 0.000 description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 4
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 4
- 229960004555 rutoside Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241000037831 Polygonatum sibiricum Species 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 230000004622 sleep time Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000018648 unbalanced nutrition Nutrition 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/70—Comminuted, e.g. emulsified, fish products; Processed products therefrom such as pastes, reformed or compressed products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种可改善微循环的营养代餐粉及其制备方法,涉及代餐粉技术领域;所述营养代餐粉按重量份数计,由以下组分制成:燕麦16‑18份、膳食纤维4‑8份、乳清蛋白粉1‑3份、荞麦3‑6份、海参粉3‑5份、黄精1.5‑2.5份、肉桂0.05‑0.2份、牛磺酸0.6‑1.5份。本发明采用燕麦、乳清蛋白粉、海参粉和荞麦制备成代餐粉,具有扩张小血管和降低血糖以及血液胆固醇的作用,能加快周身气血运行,实现体内气血充足通畅,尤其是加入黄精和桑叶后,进一步增强了代餐粉的改善微循环的功效,有利于人体健康。
Description
技术领域
本发明涉及代餐粉技术领域,具体涉及一种可改善微循环的营养代餐粉及其制备方法。
背景技术
代餐粉作为一种可取代部分或者全部正餐的食物,主要是由谷类、豆类、薯类食材等为主,其它属类植物的根、茎、果实等可食用部分为辅制成的一种单一或综合性冲调粉剂产品。代餐粉是根据人体每日膳食营养素摄入量,将每天所需要的营养食物进行合理的配比,通过减少过多的油脂、盐分及糖类的摄入所制成的一种低热量、低脂肪、均衡营养的代餐食品,并且有良好的饱腹感,适合辅助减肥或体重控制。
目前有些代餐粉虽有饱腹减肥功效,但是缺少因为人体所必须的营养物质例如蛋白质,微量元素缺乏等,长期饮用也会导致营养不均,营养不均衡问题会加重或者引发其他身体问题,长期食用此类产品,会造成营养不良,也会增加高血脂、糖尿病等的发生概率,或者引发微循环障碍。
而人体一旦发生微循环障碍,轻则处于亚健康状态,重则百病从生,例如:脑部发生微循环障碍会造成供血不足,脑细胞得不到充足的氧气和养料,代谢产物不能充分顺利排除,从而出现头晕、头痛、失眠、多梦、记忆力下降、神经衰弱等症状。
因此,提供一种能改善微循环的代餐粉能有效填补市场以及消费者的需求。
发明内容
为克服现有的技术缺陷,本发明目的在于提供一种可改善微循环的营养代餐粉及其制备方法,本发明采用燕麦、乳清蛋白粉、海参粉和荞麦制备成代餐粉,具有扩张小血管和降低血糖以及血液胆固醇的作用,能加快周身气血运行,实现体内气血充足通畅,尤其是加入黄精和桑叶后,进一步增强了代餐粉的改善微循环的功效,有利于人体健康。
为了解决上述技术问题,本发明提供了以下技术方案:
第一方面,提供了一种可改善微循环的营养代餐粉,所述代餐粉按重量份数计,由以下组分制成:
燕麦16-18份、膳食纤维4-8份、乳清蛋白粉1-3份、荞麦3-6份、海参粉3-5份、黄精1.5-2.5份、肉桂0.05-0.2份、牛磺酸0.6-1.5份。
本发明选用的原料中,荞麦中含有丰富的赖氨酸成分,铁、锰、锌等微量元素比一般谷物丰富,荞麦含有丰富的维生素E、烟酸和芦丁,能有效降低人体血脂和胆固醇、软化血管的作用。荞麦中的镁,能促进人体纤维蛋白溶解,使血管扩张,有利于改善人体微循环。
本发明进一步选用的海参粉含有丰富的精氨酸、赖氨酸、牛磺酸、钙、磷、碘、铁、锌,是人体发育成长的重要物质,能直接参与人体的生长发育、免疫调解、伤口愈合、生殖发育等生理活动,在人体能量储备和运转中起着重要作用。上述营养物质能够使人体伤口修复和再生,在医药及药理方面有重要价值。
在实验过程中,发明人意外发现,将海参粉与上述组分配合使用,能提高荞麦扩张小血管和降低血糖以及血液胆固醇的作用,使得代餐粉善人体微循环的功效进一步增强,表明海参粉与上述组分在改善微循环上具有协同增效作用。
黄精具有补气养阴、健脾、润肺、益肾功能。用于治疗脾胃虚弱、体倦乏力、口干食少、肺虚燥咳、精血不足、内热消渴等症,对于治疗糖尿病疗效显著;黄精与海参粉及上述代餐粉配合使用,能进一步提高营养代餐粉改善微循环的功效。
进一步地,所述营养代餐粉还包括桑叶1.5-3.5份。
桑叶中含有的芸香苷、槲皮素、槲皮苷能增加离体及在位蛙心的收缩力与输出量,并减少心率。芸香苷使蟾蜍下肢及兔耳血管收缩,槲皮素可扩张冠状血管,改善心肌循环。γ-氨基丁酸、芸香苷、槲皮素有降血压的作用;γ-氨基丁酸是神经传达物质,能促进脑组织的新陈代谢和恢复脑细胞功能,同时,能改善脑部血液流动,增强血管紧张素转换酶I的活性,促使血压下降。
同时,桑叶中含有强化毛细血管、降低血液黏度的黄酮类成分,有抑制脂肪肝的形成、降低血清脂肪和抑制动脉粥样硬化形成的作用。同时,桑叶中含有强化毛细血管、降低血液黏度的黄酮类成分,另外桑叶茶内含有抗体内LDL-脂蛋白氧化的成分,所以桑叶在减肥、改善高脂血症的同时,又有预防心肌梗死和脑溢血的作用。
发明人在实验中发现,桑叶中富含的功效成分与海参粉、黄精和荞麦中的营养物质具有协同增效作用,使得代餐粉善人体微循环的功效进一步增强。
进一步地,所述营养代餐粉还包括小麦苗粉1.5-3.5份。
进一步地,所述营养代餐粉还包括营养强化剂4-8份。
进一步地,所述营养强化剂选自维生素B1、维生素B2、维生素B6、维生素B12、烟酸、叶酸、泛酸、麦芽糊精中的一种或多种组合。
进一步地,所述营养代餐粉还包括食品添加剂0.05-0.1份。
进一步地,所述食品添加剂选自赤藓糖醇、羧甲基纤维素钠、磷脂、维生素C、甜菊糖苷中的一种或多种组合。
优选地,所述食品添加剂为羧甲基纤维素钠。
第二方面,提供了如第一方面所述的可改善微循环的营养代餐粉的制备方法,所述制备方法包括以下步骤:
(1)按比例称取上述原料,将除海参粉和乳清蛋白粉之外的原料,烘干后粉碎过筛,得到第一混合料,备用;
(2)取海参粉和乳清蛋白粉,过筛后加入第一混合料中,混合均匀,得到第二混合料;
(3)罐装,即得营养代餐粉。
进一步地,所述步骤(1)和(2)中,所述过筛的筛网目数为10-15目。
本发明的营养代餐粉的使用方法为:早晚各食1次,每次10克,可根据个体需要中午餐前食用10克,用温开水冲调食用即可。
与现有技术相比,本发明具有以下有益效果:
本发明采用燕麦、乳清蛋白粉、海参粉和荞麦制备成代餐粉,具有扩张小血管和降低血糖以及血液胆固醇的作用,实现体内气血充足通畅,尤其是加入黄精和桑叶后,进一步增强了代餐粉的改善微循环的功效,有利于人体健康。
本发明附加的方面和优点将在下面的描述中部分给出,这些将从下面的描述中变得明显,或通过本发明的实践了解到。
具体实施方式
为了更充分的理解本发明的技术内容,下面将结合具体实施例对本发明作进一步介绍和说明;显然,以下所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例;基于本发明中的实施例,本领域技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
对于本领域的技术人员来说,通过阅读本说明书公开的内容,本发明的特征、有益效果和优点将变得显而易见。
除非另外指明,所有百分比、分数和比率都是按本发明组合物的总重量计算的。本文术语“重量含量”可用符号“份”或“%”表示。
本文中“包括”、“包含”、“含”、“含有”、“具有”或其它变体意在涵盖非封闭式包括,这些术语之间不作区分。术语“包含”是指可加入不影响最终结果的其它步骤和成分。术语“包含”还包括术语“由...组成”和“基本上由...组成”。本发明的组合物和方法/工艺可包含、由其组成和基本上由本文描述的必要元素和限制项以及本文描述的任一的附加的或任选的成分、组分、步骤或限制项组成。
以下实施例中,所用原料组分均可通过市售购买得到的常规原料。
实施例1-5
实施例1-5提供一种可改善微循环的营养代餐粉,具体地,所述营养代餐粉中各组分的重量份数如表1所示。
表1:实施例1-5的营养代餐粉中各组分的重量份数(份)
组分 | 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 |
燕麦 | 16 | 17 | 18 | 18 | 16.5 |
膳食纤维 | 8 | 7 | 7.5 | 7 | 7.5 |
乳清蛋白粉 | 2 | 2.5 | 2 | 2.5 | 2.5 |
荞麦 | 5 | 5 | 4.5 | 4.5 | 4.5 |
海参粉 | 4.5 | 4.5 | 5 | 3.5 | 4 |
黄精 | 2.5 | 2 | 1.5 | 1.5 | 2.5 |
肉桂 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
牛磺酸 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
桑叶 | 2.5 | 2.5 | 2 | 3.5 | 3 |
小麦苗粉 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
维生素B1 | 1.5 | 2 | 2 | 1.5 | 1.5 |
维生素B2 | 1.5 | — | — | 1.5 | 1.5 |
烟酸 | 1 | 3 | — | — | 2 |
叶酸 | 1 | — | 3 | 2 | — |
羧甲基纤维素钠 | 0.08 | 0.02 | — | 0.02 | 0.08 |
赤藓糖醇 | — | — | 0.02 | 0.04 | — |
磷脂 | — | 0.03 | 0.03 | — | — |
甜菊糖苷 | — | 0.03 | 0.03 | 0.02 | — |
实施例1-5的可改善微循环的营养代餐粉的制备方法,包括以下步骤:
(1)按比例称取上述原料,将除海参粉和乳清蛋白粉之外的原料,烘干后粉碎过15目筛,得到第一混合料,备用;
(2)取海参粉和乳清蛋白粉,过15目筛后加入第一混合料中,混合均匀,得到第二混合料;
(3)罐装,即得营养代餐粉。
实施例1-5的营养代餐粉的使用方法为:早晚各食1次,每次10克,可根据个体需要中午餐前食用10克,用温开水冲调食用即可。
对比例1-4
对比例1-4提供一种可改善微循环的营养代餐粉,具体地,所述营养代餐粉中各组分的重量份数如表2所示。
表2:对比例1-4的营养代餐粉中各组分的重量份数(份)
组分 | 对比例1 | 对比例2 | 对比例3 | 对比例4 |
燕麦 | 18 | 18 | 18 | 18 |
膳食纤维 | 7.5 | 7.5 | 7.5 | 7.5 |
乳清蛋白粉 | 3 | 3 | 2 | 2 |
荞麦 | — | 6 | 5 | 5 |
海参粉 | 6 | — | 5.5 | 6 |
黄精 | 2.5 | 2.5 | — | 2 |
肉桂 | 0.15 | 0.15 | 0.15 | 0.15 |
牛磺酸 | 1.0 | 1.0 | 1.0 | 1.0 |
桑叶 | 3.5 | 3.5 | 2.5 | — |
小麦苗粉 | 2.5 | 2.5 | 2.5 | 2.5 |
维生素B1 | 2 | 2 | 2 | 2 |
叶酸 | 3 | 3 | 3 | 3 |
赤藓糖醇 | 0.02 | 0.02 | 0.02 | 0.02 |
磷脂 | 0.03 | 0.03 | 0.03 | 0.03 |
甜菊糖苷 | 0.03 | 0.03 | 0.03 | 0.03 |
其中,对比例1-4的营养代餐粉的制备方法与实施例1-5的制备方法相同。
效果试验
降血脂试验
因心血管微循环障碍主要体现在高血脂方面,因此本试验中通过测试血脂的变化体现其微循环改善效果。
具体试验步骤如下:
样品:实施例1-5以及对比例1-4的营养代餐粉;
试验对象:取雄性白鼠200只(体重160g以上),采用高脂饲料进行喂养,喂养4周后,随机分为10组;分别为空白组(喂食普通饲料)、实验组1-5(对应喂食实施例1-5的营养代餐粉)以及对照组1-4(对应喂食对比例1-4的营养代餐粉);空白组、实验组1-5和对照组1-4的白鼠连续喂食14天,并在第0和14天的相同时间测定白鼠TC含量;具体为:在用高脂饲料连续喂养4周后,各组白鼠均禁食不禁水6小时,分别在麻醉状态下股动脉采血3mL,离心分离血清,具体为采用半自动生化分析仪检测血清样品中总胆固醇的水平(mmol/L);在喂食普通饲料和代餐粉14天后,各组白鼠均禁食不禁水6小时,分别在麻醉状态下股动脉采血3mL,离心分离血清,具体为采用半自动生化分析仪检测血清样品中总胆固醇的水平(mmol/L),测试结果如表3所示。
表3:
表3中,测试数据为各组数据去掉1个最高值和1个最低值后的平均值。
根据表3的测试数据可得,在连续喂养4周后,白鼠的总胆固醇的水平较高,提示建模成功。而喂养实施例1-5的代餐粉后,实验组1-5白鼠的总胆固醇的水平相对于空白组显著下降;说明本发明通过采用燕麦、乳清蛋白粉、海参粉和荞麦制备成代餐粉,具有扩张小血管和降低血糖以及血液胆固醇的作用,能加快周身气血运行,实现体内气血充足通畅,尤其是加入黄精和桑叶后,进一步增强了代餐粉的改善微循环的功效,有利于人体健康。
而对比例1-4(对照组1-4)的代餐粉中,由于缺少了荞麦、海参粉、黄精和桑叶中的一种,并适当增加其他组分时,对照组1-4相对于空白组均具有降血脂效果,但其降血脂速度和功效均不如实施例1-5的代餐粉,这再次表明本发明在代餐粉中加入荞麦、海参粉、黄精和桑叶后,进一步增强了代餐粉的改善微循环的功效。
具体为,采用海参粉、黄精和桑叶与上述组分配合使用,海参粉、黄精和桑叶能提高荞麦扩张小血管和降低血糖以及血液胆固醇的作用,使得代餐粉善人体微循环的功效进一步增强,表明海参粉、黄精和桑叶与上述组分在改善微循环上具有协同增效作用。
改善神经系统试验
因人体神经系统微循环一旦发生障碍,会使睡眠质量变差;因此,本试验通过测试睡眠质量的改善情况体现其微循环改善效果。
具体试验步骤如下:
样品:实施例1-5以及对比例1-4的营养代餐粉;
试验对象:选取200名志愿者(男女比例1:1)进行实验,所有志愿者均有不同程度的失眠症状,将所有志愿者随机分为10组,每组20人,分别为空白组(不使用代餐粉和任何助神安眠的食品和药物)、实验组1-5(对应使用食实施例1-5的营养代餐粉)以及对照组1-4(对应使用对比例1-4的营养代餐粉),7日为一个疗程,在试验期间,志愿者饮食清淡,保持正常的作息规律。
其中,实验组1-5和对照组1-4的志愿者在早晚各食1次对应的代餐粉,每次10克,用温开水冲调食用即可,试验期间不使用任何助神安眠的食品和药物。
所有志愿者佩戴相同型号的智能手环,能收集所有志愿者的睡眠数据(试验期间,所有智能手环均能保持正常工作),其中,睡眠时间与服用前相比延长超过30%的记为显效,睡眠延长时间超过10%低于30%的记为有效,延长时间低于10%的记为无效。具体测试结果如表4(服用7天后)和表5(服用14天后)所示。
表4:服用代餐粉7天后睡眠改善情况
表5:服用代餐粉14天后睡眠改善情况
组别 | 显效 | 有效 | 无效 |
空白组 | 0 | 0 | 20 |
实验组1 | 20 | 0 | 0 |
实验组2 | 20 | 0 | 0 |
实验组3 | 20 | 0 | 0 |
实验组4 | 20 | 0 | 0 |
实验组5 | 20 | 0 | 0 |
对照组1 | 13 | 7 | 0 |
对照组2 | 14 | 6 | 0 |
对照组3 | 16 | 4 | 0 |
对照组4 | 16 | 4 | 0 |
结合表4和表5的测试结果可得,实施例1-5通过采用燕麦、乳清蛋白粉、海参粉和荞麦制备成代餐粉,具有扩张小血管和降低血糖以及血液胆固醇的作用,能加快周身气血运行,实现体内气血充足通畅,尤其是加入黄精和桑叶后,进一步增强了代餐粉的改善微循环的功效。在服用代餐粉7天后大部分志愿者的睡眠改善情况显著,在服用代餐粉14天后所有志愿者的睡眠改善情况显著;而对比例1-4(对照组1-4)的代餐粉中,由于缺少了荞麦、海参粉、黄精和桑叶中的一种,并适当增加其他组分时,对照组1-4相对于空白组均具有改善睡眠的效果,但其改善速度和功效均不如实施例1-5的代餐粉,这再次表明本发明在代餐粉中加入荞麦、海参粉、黄精和桑叶后,能进一步增强了代餐粉的改善微循环的功效。
以上对本发明实施例所提供的技术方案进行了详细介绍,本文中应用了具体个例对本发明实施例的原理以及实施方式进行了阐述,以上实施例的说明只适用于帮助理解本发明实施例的原理;同时,对于本领域的一般技术人员,依据本发明实施例,在具体实施方式以及应用范围上均会有改变之处,综上所述,本说明书内容不应理解为对本发明的限制。
Claims (10)
1.一种可改善微循环的营养代餐粉,其特征在于,按重量份数计,由以下组分制成:
燕麦16-18份、膳食纤维4-8份、乳清蛋白粉1-3份、荞麦3-6份、海参粉3-5份、黄精1.5-2.5份、肉桂0.05-0.2份、牛磺酸0.6-1.5份。
2.根据权利要求1所述的可改善微循环的营养代餐粉,其特征在于,所述营养代餐粉还包括桑叶1.5-3.5份。
3.根据权利要求1所述的可改善微循环的营养代餐粉,其特征在于,所述营养代餐粉还包括小麦苗粉1.5-3.5份。
4.根据权利要求1所述的可改善微循环的营养代餐粉,其特征在于,所述营养代餐粉还包括营养强化剂4-8份。
5.根据权利要求4所述的可改善微循环的营养代餐粉,其特征在于,所述营养强化剂选自维生素B1、维生素B2、维生素B6、维生素B12、烟酸、叶酸、泛酸、麦芽糊精中的一种或多种组合。
6.根据权利要求1所述的可改善微循环的营养代餐粉,其特征在于,所述营养代餐粉还包括食品添加剂0.05-0.1份。
7.根据权利要求6所述的可改善微循环的营养代餐粉,其特征在于,所述食品添加剂选自赤藓糖醇、羧甲基纤维素钠、磷脂、维生素C、甜菊糖苷中的一种或多种组合。
8.根据权利要求6或7所述的可改善微循环的营养代餐粉,其特征在于,所述食品添加剂为羧甲基纤维素钠。
9.一种如权利要求1-8任一项所述的可改善微循环的营养代餐粉的制备方法,其特征在于,所述制备方法包括以下步骤:
(1)按比例称取上述原料,将除海参粉和乳清蛋白粉之外的原料,烘干后粉碎过筛,得到第一混合料,备用;
(2)取海参粉和乳清蛋白粉,过筛后加入第一混合料中,混合均匀,得到第二混合料;
(3)罐装,即得营养代餐粉。
10.根据权利要求9所述的制备方法,其特征在于,所述步骤(1)和(2)中,所述过筛的筛网目数为10-15目。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210265181.5A CN114568627A (zh) | 2022-03-17 | 2022-03-17 | 一种可改善微循环的营养代餐粉及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210265181.5A CN114568627A (zh) | 2022-03-17 | 2022-03-17 | 一种可改善微循环的营养代餐粉及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114568627A true CN114568627A (zh) | 2022-06-03 |
Family
ID=81774813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210265181.5A Pending CN114568627A (zh) | 2022-03-17 | 2022-03-17 | 一种可改善微循环的营养代餐粉及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114568627A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004016092A1 (en) * | 2002-08-14 | 2004-02-26 | Bionutrigen Co., Ltd | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
CN108887566A (zh) * | 2018-08-21 | 2018-11-27 | 广州正广生物科技有限公司 | 一种无麸质的代餐粉组合物及其制备方法 |
CN113577230A (zh) * | 2021-08-08 | 2021-11-02 | 南京万舜源生物科技有限公司 | 一种预防、延缓老年痴呆症发生、发展的组合物及应用 |
-
2022
- 2022-03-17 CN CN202210265181.5A patent/CN114568627A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004016092A1 (en) * | 2002-08-14 | 2004-02-26 | Bionutrigen Co., Ltd | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
CN108887566A (zh) * | 2018-08-21 | 2018-11-27 | 广州正广生物科技有限公司 | 一种无麸质的代餐粉组合物及其制备方法 |
CN113577230A (zh) * | 2021-08-08 | 2021-11-02 | 南京万舜源生物科技有限公司 | 一种预防、延缓老年痴呆症发生、发展的组合物及应用 |
Non-Patent Citations (5)
Title |
---|
DFDFDF639: "预防, 延缓糖尿并发症", Retrieved from the Internet <URL:https://tieba.baidu.com/p/3953258865?pid=73211425440&cid=0#73211425440> * |
健餐乐: "达拜康-荞麦冲调粉,为预防及延缓糖尿病并发症而生", Retrieved from the Internet <URL:https://mp.weixin.qq.com/s/9N3x-DttUThyO9hAl4J2aQ> * |
广州健力园生物科技有限公司: "差之毫厘,失之千里:保卫微循环!(下)", Retrieved from the Internet <URL:http://www.gzjianliyuan.com/news_center.php?VID=338> * |
环球医药网: "达拜康", Retrieved from the Internet <URL:https://www.qgyyzs.net/business/zs445642.htm> * |
郭生1990: "防控并发症-健力园达拜康", Retrieved from the Internet <URL:https://v.youku.com/v_show/id_XMTMxMDE2NDg0OA==.html?playMode=pugv&frommaciku=1> * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Eshak | Sensory evaluation and nutritional value of balady flat bread supplemented with banana peels as a natural source of dietary fiber | |
CN103564562A (zh) | 果蔬发酵液、果蔬发酵饮料及其制备方法 | |
CN102058124A (zh) | 一种黄秋葵饮料及其制备方法 | |
CN101156682A (zh) | 一种排毒抗衰养生煎饼 | |
CN107853525A (zh) | 一种以魔芋膳食纤维为主的天然植物制成的多营养膳食固体饮料 | |
CN102696967A (zh) | 老年型系列杂粮杂豆免煮面与其制备方法 | |
CN103493865A (zh) | 一种适合高血压人群食用的饼干及其制备方法 | |
CN109259161A (zh) | 枸杞果酱及其加工工艺 | |
CN101569425A (zh) | 百香果醋液及其制作方法 | |
CN105768082A (zh) | 一种营养保健药膳粉 | |
CN101164426A (zh) | 一种玉米冰淇淋粉及其制备方法 | |
CN1931023A (zh) | 一种芡实蛋卷的生产方法 | |
CN114711374A (zh) | 酵纤复合营养素粉及其制备方法 | |
CN105495356A (zh) | 一种麦胚玛咖组合物及其制备工艺 | |
CN103478204A (zh) | 一种高γ-氨基丁酸饼干及其制备方法 | |
CN101455376A (zh) | 一种营养食品及其制备方法 | |
CN114568627A (zh) | 一种可改善微循环的营养代餐粉及其制备方法 | |
CN114568626A (zh) | 一种餐后血糖不升高的代餐粉及其制备方法 | |
CN102246856A (zh) | 一种火麻仁核桃乳饮料及其制备方法 | |
CN110623195A (zh) | 一种低脂肪低碳水化合物高纤维高蛋白谷物粉 | |
CN109123308A (zh) | 一种蛋白复合粉固体饮料及制做方法 | |
CN101700068B (zh) | 一种可促进儿童骨骼增长的高钙饮料的制备方法 | |
CN1088402A (zh) | 三豆粉及其制作方法 | |
KR100336650B1 (ko) | 두뇌 활성화 및 성장 촉진 기능을 강화한 생식 타입의차(茶) 조성물 | |
CN102960817A (zh) | 一种养心安神固体饮料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |